Home       Market Dynamics     You and Market     Sector Analysis     Company Insights     AI Investing     About     Contact Us     Login             

Insmed (INSM) Stock Price Prediction and News Highlight
Tue. Nov 18, 2025

The price action of Insmed (INSM) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The overall sentiment for Insmed is very positive (overall 2.8, positive 3.6, negative -0.8) on 2025-11-18. The forces of Sentiment towards Fundamentals (1.9), Stock Price Trend (1.7), Option Sentiment (1.5), Valuation Sentiment (1.5), and Sector Price Trend (1.1) will drive up the price. The forces of Price Level Sentiment (-0.5), and Market Risk Appetite (-1) will drive down the price.

'Buy the dips' is the preferred trading strategy. Hourly SMA 20 trend line is likely to provide a support from any pullbacks. The swing to upside will be significant considering the high positive sentiment forces (3.6).

The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale.


Earning Release: 2025-10-30 06:30, EPS: $-6.18, P/E: -32.62

DateAttentionAverage
Attention
PricePrice
Level
ChangeSMA10
Trend
Trend
Sentiment
Market
Sentiment
ActionFund.News
Sentiment
2025-11-180%      0%      201.62      84      2.14%      0.94%      1.7      0.9      Range      1.9      -1.5     
2025-11-170%      0%      197.4      80      2.16%      0.63%      1.3      0.6      Range      1.2      -1.5     
2025-11-160%      0%      0.4      0.4      Range      1.2      -1.5     
2025-11-150%      0%      0.4      0.3      Range      1.6      -1.5     
2025-11-140%      0%      193.22      76      1.18%      0.16%      0.4      0.5      Range      1.6      -1.5     
2025-11-130%      0%      190.96      74      -1.77%      -0.16%      0.5      0.8      Range      1.9      -1.5     
2025-11-120%      0%      194.39      83      0.36%      1.45%      2.1      0.7      Range      0      -1.5     
2025-11-110%      0%      193.69      86      0.9%      1.58%      2.3      0.6      Range      0.9      -1.5     
2025-11-100%      0%      191.96      87      1.19%      1.55%      2      0.4      Range      1.4      -1.5     
2025-11-090%      0%      2      -0.1      Short      0.4      -1.5     
 
Trend sentiment reflects the price change, and market sentiment scores are calculated from many factors. Sentiment towards fundamentals and news sentiment are extracted from news headline. All sentiment scores are normalized in a -10 - +10 scale.
The price level reaches 100 at Bollinger upper band, and zero at lower band.
Range refers to range trade strategy. In an uptrend, the price will likely bullback after huge advance. As an investor, you may want to wait for the pullback to open long position. As a trader, you may consider tactical short. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. As a trader, you may consider tactical long.

2025-11-18 17:09:44 The EMA's accelerated assessment of BRINSUPRI highlights the impact of regulatory frameworks on expediting the availability of critical therapies, underscoring the balance between safety and timely access to medications.
2025-11-18 17:09:44 The focus on therapies for rare diseases, such as Non-Cystic Fibrosis Bronchiectasis, indicates a growing market trend towards addressing unmet medical needs, reflecting shifting priorities within healthcare investment.
2025-11-18 17:09:44 Insmed's participation in healthcare conferences like Jefferies highlights the company's efforts to engage with investors and industry professionals, sharing insights and updates on their progress and developments.
2025-11-18 17:09:44 The introduction of BRINSUPRI as a first-in-class treatment illustrates the ongoing innovation within the biopharmaceutical industry, emphasizing the development of targeted therapies for serious health conditions.
2025-11-18 17:09:44 The approval of BRINSUPRI marks a significant advancement in the treatment options available for Non-Cystic Fibrosis Bronchiectasis, showcasing the importance of regulatory bodies in facilitating access to innovative therapies.


About   Contact Us  
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA